BR0104357A - Uso de receptores de toxina gbs ou fragmentos imunogênicos dela para prevenir uma condição patoangiogênica em um mamìfero - Google Patents

Uso de receptores de toxina gbs ou fragmentos imunogênicos dela para prevenir uma condição patoangiogênica em um mamìfero

Info

Publication number
BR0104357A
BR0104357A BR0104357-9A BR0104357A BR0104357A BR 0104357 A BR0104357 A BR 0104357A BR 0104357 A BR0104357 A BR 0104357A BR 0104357 A BR0104357 A BR 0104357A
Authority
BR
Brazil
Prior art keywords
gbs toxin
patoangiogenic
prevent
gbs
condition
Prior art date
Application number
BR0104357-9A
Other languages
English (en)
Inventor
Carl G Hellerqvist
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of BR0104357A publication Critical patent/BR0104357A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)

Abstract

"USO DE RECEPTORES DE TOXINA GBS OU FRAGMENTOS IMUNOGêNICOS DELA PARA PREVENIR UMA CONDIçãO PATOANGIOGêNICA EM UM MAMìFERO". São propiciados métodos para evitar ou atenuar condições patoangiogênicas pela administração de pelo menos um polipeptídeo receptor de toxina GBS ou pelo menos um fragmento imunogênico daquela. São também propiciados uma composição que inclui um polipeptídeo receptor de toxina GBS e um método para fazer tal composição. Em outra modalidade da invenção, animais imunizados também recebem toxina GBS, anticorpos imunocompatíveis ao receptor de toxina GBS e/ou células T autologas expandidas ao receptor de toxina GBS. Métodos de identificação de receptores de toxina GBS adicionais são também incluidos nesta invenção.
BR0104357-9A 2000-02-02 2001-02-02 Uso de receptores de toxina gbs ou fragmentos imunogênicos dela para prevenir uma condição patoangiogênica em um mamìfero BR0104357A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17987000P 2000-02-02 2000-02-02
PCT/US2001/003662 WO2001056598A2 (en) 2000-02-02 2001-02-02 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101)

Publications (1)

Publication Number Publication Date
BR0104357A true BR0104357A (pt) 2002-05-21

Family

ID=22658332

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0104357-9A BR0104357A (pt) 2000-02-02 2001-02-02 Uso de receptores de toxina gbs ou fragmentos imunogênicos dela para prevenir uma condição patoangiogênica em um mamìfero

Country Status (14)

Country Link
US (1) US20020061846A1 (pt)
EP (1) EP1198246B1 (pt)
JP (1) JP2003521523A (pt)
KR (1) KR20020001817A (pt)
CN (1) CN100400100C (pt)
AT (1) ATE465751T1 (pt)
AU (2) AU782853B2 (pt)
BR (1) BR0104357A (pt)
CA (1) CA2369050A1 (pt)
DE (1) DE60141938D1 (pt)
IL (1) IL145710A0 (pt)
MX (1) MXPA01009917A (pt)
NO (1) NO20014772L (pt)
WO (1) WO2001056598A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
GB0227026D0 (en) * 2002-11-20 2002-12-24 Molecular Skincare Ltd Psoriasis diagnostics and therapeutics
ES2426288T3 (es) 2003-10-15 2013-10-22 Ube Industries, Ltd. Novedoso derivado de imidazol
WO2020209920A2 (en) * 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5010062A (en) * 1989-09-25 1991-04-23 Vanderbilt University Therapeutic agent and method of inhibiting vascularization of tumors
US5858991A (en) * 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
DE69942767D1 (de) * 1998-07-22 2010-10-28 Univ Vanderbilt Gbs toxin rezeptor

Also Published As

Publication number Publication date
WO2001056598A3 (en) 2002-02-14
CN100400100C (zh) 2008-07-09
MXPA01009917A (es) 2003-08-01
IL145710A0 (en) 2002-07-25
US20020061846A1 (en) 2002-05-23
ATE465751T1 (de) 2010-05-15
CA2369050A1 (en) 2001-08-09
WO2001056598A2 (en) 2001-08-09
AU782853B2 (en) 2005-09-01
JP2003521523A (ja) 2003-07-15
EP1198246B1 (en) 2010-04-28
KR20020001817A (ko) 2002-01-09
NO20014772D0 (no) 2001-10-01
NO20014772L (no) 2001-11-12
EP1198246A2 (en) 2002-04-24
AU3481701A (en) 2001-08-14
AU2009227821A1 (en) 2009-11-05
DE60141938D1 (de) 2010-06-10
CN1372474A (zh) 2002-10-02

Similar Documents

Publication Publication Date Title
ES2141467T3 (es) Anticuerpos anti-cd 30 que impiden la escision proteolitica y liberacion del antigeno cd-30 fijado a la membrana.
DE69800716D1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
ATE264911T1 (de) Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
BR0108188A (pt) Anticorpos que se ligam a interleucina-18 humana e métodos de produção e uso
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
WO2002058717A3 (en) Methods for treating rheumatoid arthritis using il-17 antagonists
DK1539231T3 (da) Iscom-præparation og anvendelse deraf
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
HUP9903770A2 (hu) Eljárások és készítmények többepitópos antigének konformációjának megváltoztatására immunválasz kiváltása céljából
ATE328611T1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung
NO996514L (no) Overflateantigener og proteiner nyttige i sammensetninger for diagnose og forebygging av Lymesykdom
EP1433792A8 (en) Human receptor proteins, related reagents and methods
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
PT880360E (pt) Novos metodos de vacinacao e consequentes vacinas que compreendem um acido nucleico que codifica um primeiro epitopo e um peptido que contem um segundo epitopo
BR0104357A (pt) Uso de receptores de toxina gbs ou fragmentos imunogênicos dela para prevenir uma condição patoangiogênica em um mamìfero
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
BR9507426A (pt) Composição de inibina e processos para uso das mesmas
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
OA08334A (fr) Protéines de différentiation acino-foetales associées au cancer du pancréas, antisérum et anticorps monoclonaux contre ces protéines, procédés de préparation.
ES2164231T3 (es) Antigeno de helicobacter pylori.
PT97179A (pt) Processo para a preparacao de anticorpos monoclonias anti-oncostatina m
GB9715177D0 (en) Medicament
BR9810574A (pt) Anticorpo monoclonal, fragmento de anticorpo, mistura ou derivado destes, uso dos mesmos, célula, e, preparação farmacêutica.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A., 9A., 10A. E 11A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.